Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19
Paul Balfanz(RWTH Aachen University), Michael Dreher(American Thoracic Society), Tobias Müller(Heidelberg University), Johannes Bickenbach(RWTH Aachen University), Dennis Häckl(Research Institute for System Studies), Bojan Hartmann(Universitätsklinikum Aachen), Gernot Marx(RWTH Aachen University), Nils Kossack(Research Institute for System Studies), Dirk Müller‐Wieland(Universitätsklinikum Aachen), Michael Kleines(Universitätsklinikum Aachen), Christian Cornélissen(RWTH Aachen University), Ayham Daher(RWTH Aachen University), Nikolaus Marx(RWTH Aachen University), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Alexander Kersten
Cited by 16
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
|Critical Care|2013|1.4k
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study
|The Lancet Respiratory Medicine|2020|864